# XIAP

## Overview
XIAP, or X-linked inhibitor of apoptosis protein, is a crucial cellular protein encoded by the XIAP gene located on the X chromosome. It plays a pivotal role in the inhibition of apoptosis, primarily through its interaction with caspases, which are central to the programmed cell death pathway. The protein is characterized by several Baculoviral IAP Repeat (BIR) domains that mediate these interactions and a RING domain that confers E3 ubiquitin ligase activity, targeting proteins for degradation and thus regulating apoptosis at multiple levels (Eckelman2006Human; Moore2009Structural). XIAP's ability to bind and inhibit caspases-3, -7, and -9 is essential for its role in blocking the apoptotic process, thereby contributing to cell survival and homeostasis (GalbÃ¡n2009XIAP). Additionally, XIAP interacts with other signaling pathways, enhancing its importance beyond apoptosis, including in immune response and inflammation (Harlin2001Characterization).

## Structure
The molecular structure of the XIAP protein is characterized by multiple Baculoviral IAP Repeat (BIR) domains and a RING domain. The BIR domains, specifically BIR2 and BIR3, are crucial for the protein's function in inhibiting apoptosis by interacting with caspases. The BIR2 domain consists of a three-stranded antiparallel beta-sheet and four alpha-helices, stabilized by zinc chelation involving conserved amino acids and by hydrophobic interactions within the core of the protein (Sun1999NMR). The BIR3 domain, while similar in its basic zinc finger-like structure, comprises five alpha-helices and a three-stranded beta-sheet, with specific residues critical for the inhibition of different caspases (Sun2000NMR).

The RING domain of XIAP functions as an E3 ubiquitin ligase, which is involved in the ubiquitination and targeting of substrates for proteasomal degradation, contributing to the regulation of apoptosis (Moore2009Structural). Post-translational modifications such as phosphorylation, ubiquitination, and sumoylation affect XIAP's stability and interaction with other proteins, enhancing its functional versatility in apoptosis inhibition pathways.

Splice variants of XIAP result in different isoforms that may differ in their apoptotic inhibition efficiency and tissue distribution, reflecting the complexity and regulatory capacity of this protein in cellular contexts.

## Function
XIAP, or X-linked inhibitor of apoptosis protein, plays a critical role in the inhibition of apoptosis, primarily through its interaction with caspases, which are key enzymes in the programmed cell death pathway. XIAP uses its baculoviral IAP repeat (BIR) domains to bind to and inhibit caspases-3, -7, and -9, effectively blocking their proteolytic activity and preventing the initiation of the apoptosis cascade (Eckelman2006Human; GalbÃ¡n2009XIAP). The BIR3 domain of XIAP specifically inhibits caspase-9 by preventing its dimerization and activation, a necessary step for its apoptotic function (Eckelman2006Human). 

Beyond its role in apoptosis, XIAP is also involved in other cellular signaling pathways. It functions as an E3 ubiquitin ligase, a role that extends its influence to the ubiquitin-proteasome degradation pathway, impacting various cellular processes (GalbÃ¡n2009XIAP). XIAP's interaction with components of the TGF-Î² signaling pathway and its involvement in the NF-kB pathway, crucial for immune response and inflammation, highlight its multifunctional nature and importance in cellular signaling beyond just apoptosis suppression (GalbÃ¡n2009XIAP; Harlin2001Characterization). 

These molecular functions of XIAP are essential for maintaining cellular homeostasis and responding to physiological stress, underscoring its pivotal role in cell biology and organismal outcomes.

## Clinical Significance
Mutations in the XIAP gene, which encodes the X-linked inhibitor of apoptosis protein, are primarily associated with X-linked lymphoproliferative syndrome type 2 (XLP-2). This rare inherited immunodeficiency is characterized by an increased susceptibility to Epstein-Barr virus (EBV) infections, which can trigger severe immune responses such as hemophagocytic lymphohistiocytosis (HLH). Affected individuals often exhibit symptoms like splenomegaly, hypogammaglobulinemia, and lymphomas (Rigaud2006XIAP; Damgaard2012The).

XIAP deficiency also leads to a specific defect in the number of natural killer T (NKT) cells, which does not affect the percentages of natural killer (NK) cells, distinguishing it from other similar immunodeficiencies (Rigaud2006XIAP). Furthermore, XIAP mutations result in defective NOD signaling due to improper interaction with RIP2 protein, crucial for controlling mucosal homeostasis and inflammation, particularly in the gastrointestinal tract. This defective interaction underpins the pathogenesis of inflammatory bowel disease (IBD), including conditions resembling Crohn's disease, in XIAP-deficient patients (Lee2024Understanding; Hrdinka2019Inhibitor).

In addition to immune dysregulation, XIAP mutations disrupt apoptosis regulation, leading to increased cell death in T lymphocytes and contributing to the pathology of diseases like Crohn's disease (Parackova2020Novel). The only current effective treatment for severe cases of XIAP deficiency is hematopoietic stem cell transplantation, as other medical treatments have shown minimal or only temporary effects (Lee2024Understanding).

## Interactions
XIAP (X-linked inhibitor of apoptosis protein) interacts with several proteins to regulate apoptosis, primarily through its BIR (Baculovirus IAP Repeat) domains. The BIR3 domain of XIAP binds to the processed form of caspase-9 at its N-terminal tetra-peptide, inhibiting caspase-9 activity by blocking substrate entry to the active site (Srinivasula2001A). This interaction is crucial for preventing the formation of the catalytically active caspase-9 homodimer, essential for the mitochondrial pathway of apoptosis (Oost2004Discovery).

Additionally, XIAP's interaction with Smac/DIABLO, another apoptosis-related protein, involves competitive binding to the BIR3 domain. This interaction disrupts the XIAP-caspase-9 complex, promoting apoptosis by freeing caspase-9 (Liu2000Structural). Smac/DIABLO binds more extensively with the BIR3 domain compared to caspase-9, enhancing its ability to relieve caspase-9 inhibition (Srinivasula2001A).

XIAP also interacts with RIP2, binding through its BIR2 domain. This interaction facilitates XIAP's association with NOD1 and NOD2 proteins, which are part of the immune response signaling pathways (Krieg2009XIAP). Furthermore, XIAP forms complexes with other IAP family members like cIAP2, enhancing protein stability in specific cancer cells (Cheung2020Anti-apoptotic). These interactions highlight XIAP's role in both inhibiting apoptosis and modulating other cellular signaling pathways.


## References


[1. (Parackova2020Novel) Zuzana Parackova, Tomas Milota, Petra Vrabcova, Jitka Smetanova, Michael Svaton, Tomas Freiberger, Veronika Kanderova, and Anna Sediva. Novel xiap mutation causing enhanced spontaneous apoptosis and disturbed nod2 signalling in a patient with atypical adult-onset crohnâs disease. Cell Death &amp; Disease, June 2020. URL: http://dx.doi.org/10.1038/s41419-020-2652-4, doi:10.1038/s41419-020-2652-4. (17 citations) 10.1038/s41419-020-2652-4](https://doi.org/10.1038/s41419-020-2652-4)

[2. (Sun1999NMR) Chaohong Sun, Mengli Cai, Angelo H. Gunasekera, Robert P. Meadows, Hong Wang, Jun Chen, Haichao Zhang, Wei Wu, Nan Xu, Shi-Chung Ng, and Stephen W. Fesik. Nmr structure and mutagenesis of the inhibitor-of-apoptosis protein xiap. Nature, 401(6755):818â822, October 1999. URL: http://dx.doi.org/10.1038/44617, doi:10.1038/44617. (533 citations) 10.1038/44617](https://doi.org/10.1038/44617)

[3. (Liu2000Structural) Zhihong Liu, Chaohong Sun, Edward T. Olejniczak, Robert P. Meadows, Stephen F. Betz, Thorsten Oost, Julia Herrmann, Joe C. Wu, and Stephen W. Fesik. Structural basis for binding of smac/diablo to the xiap bir3 domain. Nature, 408(6815):1004â1008, December 2000. URL: http://dx.doi.org/10.1038/35050006, doi:10.1038/35050006. (862 citations) 10.1038/35050006](https://doi.org/10.1038/35050006)

[4. (Oost2004Discovery) Thorsten K. Oost, Chaohong Sun, Robert C. Armstrong, Ali-Samer Al-Assaad, Stephen F. Betz, Thomas L. Deckwerth, Hong Ding, Steven W. Elmore, Robert P. Meadows, Edward T. Olejniczak, Andrew Oleksijew, Tilman Oltersdorf, Saul H. Rosenberg, Alexander R. Shoemaker, Kevin J. Tomaselli, Hua Zou, and Stephen W. Fesik. Discovery of potent antagonists of the antiapoptotic protein xiap for the treatment of cancer. Journal of Medicinal Chemistry, 47(18):4417â4426, July 2004. URL: http://dx.doi.org/10.1021/jm040037k, doi:10.1021/jm040037k. (500 citations) 10.1021/jm040037k](https://doi.org/10.1021/jm040037k)

[5. (Eckelman2006Human) Brendan P Eckelman, Guy S Salvesen, and Fiona L Scott. Human inhibitor of apoptosis proteins: why xiap is the black sheep of the family. EMBO reports, 7(10):988â994, August 2006. URL: http://dx.doi.org/10.1038/sj.embor.7400795, doi:10.1038/sj.embor.7400795. (1117 citations) 10.1038/sj.embor.7400795](https://doi.org/10.1038/sj.embor.7400795)

[6. (Moore2009Structural) Cathy D. Moore, Haihong Wu, Ben BolaÃ±os, Simon Bergqvist, Alexei Brooun, Tom Pauly, and Dawn Nowlin. Structural and biophysical characterization of xiap bir3 g306e mutant: insights in protein dynamics and application for fragmentâbased drug design. Chemical Biology &amp; Drug Design, 74(3):212â223, August 2009. URL: http://dx.doi.org/10.1111/j.1747-0285.2009.00862.x, doi:10.1111/j.1747-0285.2009.00862.x. (16 citations) 10.1111/j.1747-0285.2009.00862.x](https://doi.org/10.1111/j.1747-0285.2009.00862.x)

[7. (Krieg2009XIAP) Andreas Krieg, Ricardo G. Correa, Jason B. Garrison, GaÃ«lle Le Negrate, Kate Welsh, Ziwei Huang, Wolfram T. Knoefel, and John C. Reed. Xiap mediates nod signaling via interaction with rip2. Proceedings of the National Academy of Sciences, 106(34):14524â14529, August 2009. URL: http://dx.doi.org/10.1073/pnas.0907131106, doi:10.1073/pnas.0907131106. (249 citations) 10.1073/pnas.0907131106](https://doi.org/10.1073/pnas.0907131106)

[8. (Cheung2020Anti-apoptotic) Chun Hei Antonio Cheung, Yung-Chieh Chang, Tzu-Yu Lin, Siao Muk Cheng, and Euphemia Leung. Anti-apoptotic proteins in the autophagic world: an update on functions of xiap, survivin, and bruce. Journal of Biomedical Science, February 2020. URL: http://dx.doi.org/10.1186/s12929-020-0627-5, doi:10.1186/s12929-020-0627-5. (71 citations) 10.1186/s12929-020-0627-5](https://doi.org/10.1186/s12929-020-0627-5)

[9. (Sun2000NMR) Chaohong Sun, Mengli Cai, Robert P. Meadows, Nan Xu, Angelo H. Gunasekera, Julia Herrmann, Joe C. Wu, and Stephen W. Fesik. Nmr structure and mutagenesis of the third bir domain of the inhibitor of apoptosis protein xiap. Journal of Biological Chemistry, 275(43):33777â33781, October 2000. URL: http://dx.doi.org/10.1074/jbc.m006226200, doi:10.1074/jbc.m006226200. (406 citations) 10.1074/jbc.m006226200](https://doi.org/10.1074/jbc.m006226200)

[10. (Srinivasula2001A) Srinivasa M. Srinivasula, Ramesh Hegde, Ayman Saleh, Pinaki Datta, Eric Shiozaki, Jijie Chai, Ryung-Ah Lee, Paul D. Robbins, Teresa Fernandes-Alnemri, Yigong Shi, and Emad S. Alnemri. A conserved xiap-interaction motif in caspase-9 and smac/diablo regulates caspase activity and apoptosis. Nature, 410(6824):112â116, March 2001. URL: http://dx.doi.org/10.1038/35065125, doi:10.1038/35065125. (775 citations) 10.1038/35065125](https://doi.org/10.1038/35065125)

[11. (Damgaard2012The) Rune Busk Damgaard, Ueli Nachbur, Monica Yabal, Wendy Wei-Lynn Wong, Berthe Katrine Fiil, Mischa Kastirr, Eva Rieser, James Arthur Rickard, Aleksandra Bankovacki, Christian Peschel, Juergen Ruland, Simon Bekker-Jensen, Niels Mailand, Thomas Kaufmann, Andreas Strasser, Henning Walczak, John Silke, Philipp J. Jost, and Mads Gyrd-Hansen. The ubiquitin ligase xiap recruits lubac for nod2 signaling in inflammation and innate immunity. Molecular Cell, 46(6):746â758, June 2012. URL: http://dx.doi.org/10.1016/j.molcel.2012.04.014, doi:10.1016/j.molcel.2012.04.014. (326 citations) 10.1016/j.molcel.2012.04.014](https://doi.org/10.1016/j.molcel.2012.04.014)

[12. (Rigaud2006XIAP) StÃ©phanie Rigaud, Marie-Claude FondanÃ¨che, Nathalie Lambert, Benoit Pasquier, VÃ©ronique Mateo, Pauline Soulas, Lionel Galicier, FranÃ§oise Le Deist, FrÃ©dÃ©ric Rieux-Laucat, Patrick Revy, Alain Fischer, GeneviÃ¨ve de Saint Basile, and Sylvain Latour. Xiap deficiency in humans causes an x-linked lymphoproliferative syndrome. Nature, 444(7115):110â114, November 2006. URL: http://dx.doi.org/10.1038/nature05257, doi:10.1038/nature05257. (779 citations) 10.1038/nature05257](https://doi.org/10.1038/nature05257)

[13. (Lee2024Understanding) Juhwan Lee, Kyoung Mi Sim, Mooseok Kang, Hyun Ju Oh, Ho Jung Choi, Yeong Eun Kim, Chan-Gi Pack, Kyunggon Kim, Kyung Mo Kim, Seak Hee Oh, Inki Kim, and Iksoo Chang. Understanding the molecular mechanism of pathogenic variants of bir2 domain in xiap-deficient inflammatory bowel disease. Scientific Reports, January 2024. URL: http://dx.doi.org/10.1038/s41598-023-50932-5, doi:10.1038/s41598-023-50932-5. (0 citations) 10.1038/s41598-023-50932-5](https://doi.org/10.1038/s41598-023-50932-5)

[14. (Hrdinka2019Inhibitor) Matous Hrdinka and Monica Yabal. Inhibitor of apoptosis proteins in human health and disease. Genes &amp; Immunity, 20(8):641â650, May 2019. URL: http://dx.doi.org/10.1038/s41435-019-0078-8, doi:10.1038/s41435-019-0078-8. (40 citations) 10.1038/s41435-019-0078-8](https://doi.org/10.1038/s41435-019-0078-8)

[15. (GalbÃ¡n2009XIAP) S GalbÃ¡n and C S Duckett. Xiap as a ubiquitin ligase in cellular signaling. Cell Death &amp; Differentiation, 17(1):54â60, July 2009. URL: http://dx.doi.org/10.1038/cdd.2009.81, doi:10.1038/cdd.2009.81. (279 citations) 10.1038/cdd.2009.81](https://doi.org/10.1038/cdd.2009.81)

[16. (Harlin2001Characterization) Helena Harlin, Stephanie Birkey Reffey, Colin S. Duckett, Tullia Lindsten, and Craig B. Thompson. Characterization of xiap-deficient mice. Molecular and Cellular Biology, 21(10):3604â3608, May 2001. URL: http://dx.doi.org/10.1128/mcb.21.10.3604-3608.2001, doi:10.1128/mcb.21.10.3604-3608.2001. (560 citations) 10.1128/mcb.21.10.3604-3608.2001](https://doi.org/10.1128/mcb.21.10.3604-3608.2001)